Uncategorized
Eylea receives approval for macular edema secondary to retinal vein occlusion in Europe
The European Commission has approved Eylea for the treatment of visual impairment due to macular edema following retinal vein occlusion, according to a press release from Regeneron.Eylea (aflibercept) was previously approved for macular edema secondary to central retinal vein occlusion. Macular edema following branch retinal vein occlusion is included in the new indication.